Investigating why lung cancer outcomes differ for patients of African ancestry
Molecular mediators of disparate outcomes experienced by patients of African ancestry with lung cancer
This study is looking at why lung cancer might be harder to treat for patients of African ancestry by examining their tumor samples and genetics, and it hopes to find ways to improve treatments for them while also addressing the lack of representation of African Americans in clinical trials.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11023305 on NIH RePORTER |
What this research studies
This research focuses on understanding the unique molecular factors that contribute to poorer lung cancer outcomes in patients of African ancestry. By analyzing tumor samples and genomic profiles, the study aims to identify specific genetic alterations that may lead to therapeutic resistance. The research will also explore the underrepresentation of African Americans in clinical trials and how this impacts treatment efficacy. Ultimately, the goal is to uncover insights that could improve treatment strategies for this population.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals of African ancestry who have been diagnosed with lung cancer.
Not a fit: Patients of non-African ancestry or those without a lung cancer diagnosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective lung cancer treatments tailored for patients of African ancestry.
How similar studies have performed: Previous research has indicated that understanding genetic differences can lead to improved treatment outcomes, suggesting potential success for this approach.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Mcgrail, Daniel James — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Mcgrail, Daniel James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.